We also assessed whether bortezomib can neutralize the suppression of T cell cytolytic molecule expression mediated in the tumor microenvironment by the immunosuppressive cytokine TGFβ via the Smad-ATF1 pathway [47]. The gene discussed is TGFB1; the disease is neoplasm.